Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 6, 2017, Pages 960-968

  Schmuck, Sebastian ^a   Nordlohne, Stefan ^a   von Klot, Christoph A ^a   Henkenberens, Christoph ^a   Sohns, Jan M ^a   Christiansen, Hans ^a   Wester, Hans Jürgen ^b   Ross, Tobias L ^a   Bengel, Frank M ^a   Derlin, Thorsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Delayed imaging; Detection rate; Dual phase imaging; PET CT; Prostate cancer; PSMA

Indexed keywords

ANTINEOPLASTIC AGENT; FUROSEMIDE; GALLIUM 68; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; 68GA-DOTAGA-(3-IODO-Y)FK(SUB-KUE); COORDINATION COMPOUND; OLIGOPEPTIDE;

ABDOMINAL RADIOGRAPHY; ADRENAL METASTASIS; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPARATIVE STUDY; CRYOSURGERY; DIAGNOSTIC IMAGING; ELECTROPORATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMAGE RECONSTRUCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCLE METASTASIS; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; TESTICULAR METASTASIS; TESTIS CANCER; TRANSURETHRAL RESECTION; URINARY EXCRETION; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RECURRENT DISEASE; STANDARD; STANDARDS; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COORDINATION COMPLEXES; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OLIGOPEPTIDES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85014714066     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-017-3669-5     Document Type: Article

References (28)

1. Torre LA, Bray F, Siegel RL, et al. Global Cancer Statistics, 2012. Ca – a Cancer J Clin. 2015;65:87–108.
2. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387(10013):70–82.
3. Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, et al. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urol Oncol. 2016;34:119.e11–8.
4. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607–11.
5. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9.
6. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.
7. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
8. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668–74.
9. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015;56:1169–76.
10. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.
11. Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, et al. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clin Nucl Med. 2016;41(9):e397–402.
12. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13.
13. Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017;44:670–77.
14. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.
15. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651–8.
16. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.
17. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11:14–23.
18. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–41.
19. Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345–53.
20. 68Ga]CPCR4.2. Nucl Med Biol. 2014;41:84–9.
21. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14.
22. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713–9.
23. 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898–905.
24. Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. EJNMMI Phys. 2014;1:99.
25. Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20.
26. Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, et al. Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake. J Nucl Med. 2016. PMID: 27932557.
27. Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of 18F- and 68Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer. J Nucl Med. 2016. PMID: 27908968.
28. Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation Negative on Ga-68-PSMA PET/CT. Clin Nucl Med. 2015;40:E163–6.